Contact us today
Monday to Friday, 5:30 AM – 5:00 PM (PST)
PROSIGNA PRODUCT INSERTS AND MSDS
Download the Prosigna Product Insert
Download the nCounter
Hybridization Buffer MSDS
Download the nCounter Prep
Download the nCounter
Reporter CodeSet MSDS
Download the nCounter
Download the nCounter DX
Analysis System User Manual
Download the Prosigna
Product Data Sheet
Download the RNA Reference Samples and Training Samples Datasheet
Scientific Evidence Of The Prosigna Assay’s Clinical Performance
More comprehensive information for better treatment decisions
OPTIMA (Optimal Personalized
Treatment of early breast cancer using Multi-parameter Analysis) Clinical Trial
Personalized Radiation Therapy
for Low-risk Early Breast
Cancer) Clinical Trial
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype- Prosigna® Test in the management of early-stage breast cancers
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (NICE Diagnostic Guidance)
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Molecular Divers of Onco Type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
Select one of the nationally accessible labs below to learn more about how you can have the Prosigna breast cancer assay performed on the locally available nCounter Dx Analysis System.
HEALTH INSURANCE COVERAGE
The Prosigna Breast Cancer Assay is covered by Medicare and commercial payers for patients
meeting the indications for use
To find out if the Prosigna test is covered in your country and for more information on your reimbursement status or private insurance options, please get in touch with our customer care team.
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany
This website contains information on products which is targeted to a wide range of audiences
and could contain product details or information otherwise not accessible or valid in your country.
Please be aware that we do not take any responsibility for accessing such information which may
not comply with any legal process, regulation, registration or usage in the country of your origin.
© 2022 Veracyte, Inc. All rights reserved.
Prosigna, Veracyte, the Prosigna logo, and the Veracyte logo are registered trademarks of Veracyte.